|
KR20170123696A
|
|
Composition and method for treating complement related diseases
|
|
EP3035934A2
|
|
Compositions and therapeutic methods for accelerated plaque regression
|
|
WO2015025228A2
|
|
Compositions and therapeutic methods for accelerated plaque regression
|
|
WO2014060852A2
|
|
Compounds useful in the synthesis of benzamide compounds
|
|
NZ623381A
|
|
Oral immediate release formulations for substituted quinazolinones
|
|
BRPI1014956A2
|
|
anti-inflammatory agents
|
|
KR20120003889A
|
|
Novel anti-inflammatory agents
|
|
WO2010079431A2
|
|
Compounds for the prevention and treatment of cardiovascular disease
|
|
MX341422B
|
|
Compounds for the prevention and treatment of cardiovascular diseases.
|
|
CN101970416A
|
|
Methods of preparing quinazolinone derivatives
|
|
NZ579355A
|
|
2-(Aryl)-4-oxo-quinazoline derivatives
|
|
CN103319408A
|
|
Compounds for preventing and treating cardiovascular diseases
|
|
NZ597776A
|
|
Compounds for the prevention and treatment of cardiovascular diseases
|
|
AU2006275514A1
|
|
Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
|
|
EP2332527A2
|
|
Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
|
|
MXPA06003838A
|
|
Treatment of diseases associated with the egr-1 enhancer element.
|
|
CA2545479A1
|
|
Compounds comprising a nitric oxide moiety for inducing expression of apoa1 for the treatment of cardiovascular disorders
|
|
CN1893957A
|
|
Nitric oxide donating derivatives for the treatment of cardiovascular disorders
|
